Scholarlink

<p>Hypertension is a widespread chronic illness. Hypertension is significantly associated with thromboembolic disease, including venous thromboembolism (VTE), pulmonary embolism (PE), and arterial embolism, and confers a markedly increased risk of thromboembolic events. We seek to assess demographic and regional disparities and analyze the mortality trends in hypertension-associated thromboembolism-related mortality among adults in the United States from 1999 to 2023. We obtained death certificate data from the CDC wonder MCOD database for patients with coexisting thromboembolism and hypertension, from 1999–2023.AAMRs (age-adjusted mortality rates) were calculated, and standardized to 2000 U.S. population. The Joinpoint Regression Program was used to calculate APCs (annual percent changes). Data was stratified with various demographic and geographic variables. In total, 187,872 deaths with both thromboembolism and hypertension on their death certificates occurred in the United States between 1999 and 2023. Age-adjusted mortality rates increased substantially throughout the study period in both men and women, rising from 0.9 to 5.9 deaths per 100,000 in men, with men consistently experiencing higher rates than women. Among racial groups, NH African Americans bore the greatest mortality burden (AAMR 6.7). Older adults (aged ≥ 65) had markedly higher AAMRs, approximately 6.5 times those of middle-aged adults and 62 times those of young adults. Geographic analysis revealed elevated age-adjusted mortality rates in nonmetropolitan areas (3.3) and the Southern region (3.6), with the District of Columbia exhibiting the highest rate overall (7.5). These disparities across demographic and geographical variables necessitate appropriate resource allocation and targeted interventions to reduce the hypertension-associated thromboembolism mortality burden.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Growing mortality divide: demographic and regional disparities in thromboembolism with hypertension, U.S. 1999–2023

  • 期刊论文

  • 发表日期：

    2026年3月7日

查看全文
  • Muhammad Shaheer Bin Faheem,
  • Own E. Mohammad Najmi,
  • Usman Ahmad,
  • Mahad Ahmad,
  • Ammar Yahya,
  • Sanhia Maheshwari,
  • Ashish Ashok Lal

摘要

Hypertension is a widespread chronic illness. Hypertension is significantly associated with thromboembolic disease, including venous thromboembolism (VTE), pulmonary embolism (PE), and arterial embolism, and confers a markedly increased risk of thromboembolic events. We seek to assess demographic and regional disparities and analyze the mortality trends in hypertension-associated thromboembolism-related mortality among adults in the United States from 1999 to 2023. We obtained death certificate data from the CDC wonder MCOD database for patients with coexisting thromboembolism and hypertension, from 1999–2023.AAMRs (age-adjusted mortality rates) were calculated, and standardized to 2000 U.S. population. The Joinpoint Regression Program was used to calculate APCs (annual percent changes). Data was stratified with various demographic and geographic variables. In total, 187,872 deaths with both thromboembolism and hypertension on their death certificates occurred in the United States between 1999 and 2023. Age-adjusted mortality rates increased substantially throughout the study period in both men and women, rising from 0.9 to 5.9 deaths per 100,000 in men, with men consistently experiencing higher rates than women. Among racial groups, NH African Americans bore the greatest mortality burden (AAMR 6.7). Older adults (aged ≥ 65) had markedly higher AAMRs, approximately 6.5 times those of middle-aged adults and 62 times those of young adults. Geographic analysis revealed elevated age-adjusted mortality rates in nonmetropolitan areas (3.3) and the Southern region (3.6), with the District of Columbia exhibiting the highest rate overall (7.5). These disparities across demographic and geographical variables necessitate appropriate resource allocation and targeted interventions to reduce the hypertension-associated thromboembolism mortality burden.